Pathology of Breast andOvarian Cancers among BRCA 1 and BRCA 2 Mutation Carriers : Results from the Consortium of Investigators of Modi fi ers of BRCA 1 / 2 ( CIMBA )
N. Mavaddat,D. Barrowdale,I. Andrulis,S. Domchek,D. Eccles,H. Nevanlinna,S. Ramus,A. Spurdle,M. Robson,M. Sherman,Anna Marie,Mulligan,F. Couch,C. Engel,L. McGuffog
Abstract:Background: Previously, small studies have found that BRCA1 and BRCA2 breast tumors differ in their pathology. Analysis of larger datasets of mutation carriers should allow further tumor characterization. Methods:We used data from 4,325 BRCA1 and 2,568 BRCA2 mutation carriers to analyze the pathology of invasive breast, ovarian, and contralateral breast cancers. Results: There was strong evidence that the proportion of estrogen receptor (ER)-negative breast tumors decreased with age at diagnosis among BRCA1 (P-trend 1⁄4 1.2 10 ), but increased with age at diagnosis among BRCA2, carriers (P-trend1⁄4 6.8 10 ). The proportion of triple-negative tumors decreasedwith age at diagnosis in BRCA1 carriers but increased with age at diagnosis of BRCA2 carriers. In both BRCA1 and BRCA2 carriers, ER-negative tumors were of higher histologic grade than ER-positive tumors (grade 3 vs. grade 1; P1⁄4 1.2 10 13 for BRCA1 and P 1⁄4 0.001 for BRCA2). ER and progesterone receptor (PR) expression were independently associated with mutation carrier status [ER-positive odds ratio (OR) for BRCA2 1⁄4 9.4, 95% CI: 7.0–12.6 and PR-positiveOR1⁄4 1.7, 95%CI: 1.3–2.3, under joint analysis]. Lobular tumorsweremore likely to be BRCA2-related (OR for BRCA2 1⁄4 3.3, 95% CI: 2.4–4.4; P 1⁄4 4.4 10 ), and medullary tumors BRCA1-related (OR for BRCA21⁄4 0.25, 95% CI: 0.18–0.35; P1⁄4 2.3 10 ). ER-status of the first breast cancer was predictive of ER-status of asynchronous contralateral breast cancer (P1⁄4 0.0004 forBRCA1;P1⁄4 0.002 forBRCA2). Therewere no significant differences in ovarian cancer morphology between BRCA1 and BRCA2 carriers (serous: 67%; mucinous: 1%; endometrioid: 12%; clear-cell: 2%). Conclusions/Impact: Pathologic characteristics of BRCA1 and BRCA2 tumors may be useful for improving risk-prediction algorithms and informing clinical strategies for screening and prophylaxis. Cancer Epidemiol Biomarkers Prev; 21(1); 134–47. 2011 AACR. Cancer Clinic, Netherlands Cancer Institute, Amsterdam; Department of Medical Oncology, Family Cancer Clinic, Erasmus University Medical Center, Rotterdam; Department of Medical Genetics, University Medical Center Utrecht, Utrecht, TheNetherlands; GeneticMedicine,Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHSFoundation Trust,Manchester; Department of Clinical Genetics, Royal Devon & Exeter Hospital, Exeter; Oxford Regional Genetics Service, Churchill Hospital, Oxford; All Wales Medical Genetics Services, University Hospital of Wales, Cardiff; North East Thames Regional Genetics Service, Great Ormond Street Hospital for Children NHS Trust, London; Cheshire & Merseyside Clinical Genetics Service, Liverpool Women's NHS Foundation Trust, Liverpool, United Kingdom; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas; Centre of Familial Breast and Ovarian Cancer, Department of Gynaecology and Obstetrics and Centre for Integrated Oncology (CIO), University Hospital of Cologne, Cologne; Department of Gynaecology andObstetrics, Division of Tumor Genetics, Klinikum rechts der Isar, Technical University Munich, Munich; Department of Gynaecology andObstetrics, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden; Institute of Human Genetics, University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel; Department of Gynaecology and Obstetrics, University Hospital D€ usseldorf, Heinrich-Heine University D€ usseldorf, D€ usseldorf; Department of Gynaecology and Obstetrics, University Hospital Ulm, Ulm; Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover; Institute of Human Genetics, University of M€ unster, M€ unster; Institute of Human Genetics, Campus Virchov Klinikum, Charite Berlin; Centre of Familial Breast and Ovarian Cancer, Department of Medical Genetics, Institute of Human Genetics, University W€ urzburg, W€ urzburg, Germany; Institute of Cancer Research, Surrey, United Kingdom; Service de G en etique Oncologique, Unit e INSERM U830, Institut Curie; Universit e Paris Descartes, Facult e de M edecine, Paris, France; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia; Hereditary Cancer Program, Institut Catal a d'Oncologia, Germans Trias i Pujol Biopmedical research Institute (IGTP), Badalona; Hereditary Cancer Program, Institut Catal a d'Oncologia, Hospital Duran i Reynals Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona; Hereditary Cancer Program, Institut Catal a d'Oncologia, Hospital Josp Trueta Girona Biomedical Research Institute (IdiBGi), Girona, Spain; Department of Pathology, Landspitali, University Hospital and Faculty of Medicine, University of Iceland, Reykjavik, Iceland; Cancer Genomics Laboratory, Canada Research Chair in Oncogenetics, Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Qu ebec and Laval University, Quebec City, Quebec, Canada; Immunology and Molecular Oncology Unit, Istituto Oncologico Veneto IOV IRCCS; Department of Oncology and Surgical Sciences, University of Padua and Istituto Oncologico Veneto IOV IRCCS, Padua, Italy; Department of Anatomical Pathology, Prince of Wales Hospital, Randwick, New South Wales, Australia. 85Center for Medical Genetics, North Shore University Health System, Evanston, Illinois; Medical Oncology, Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute, Boston, Massachusetts; University of Delaware, Newark, Delaware; Epidemiology Research Program, American Cancer Society, Atlanta, Georgia; Dept. of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology and Department of Medical Genetics, St. Petersburg Pediatric Medical Academy, St. Petersburg, Russia; Department of Molecular Virology, Immunology and Medical Genetics, Department of Internal Medicine, Division of Human Genetics, Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, Ohio; Department of Clinical Genetics, Odense University Hospital, Odense, Denmark; Section of Genetic Oncology, Dept. of Laboratory Medicine, University and University Hospital of Pisa, Pisa, Italy; Departments of Clinical Genetics and Oncology, Karolinska University Hospital; Karolinska University, Stockholm; Oncological Centre, Lund University Hospital, Lund, Sweden; Department of Population Sciences, Beckman Research Institute of the City of Hope, Duarte; Department of Medicine, Division of Medical Genetics; Departments of Medicine, Epidemiology, and Biostatistics, University of California, San Francisco, California; and Departments of Gynecologic Oncology and Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York Note: Supplementary data for this article are available at Cancer Epidemiology, Biomarkers & Prevention Online (http://cebp.aacrjournals.org/). Corresponding Author: Antonis C. Antoniou, Strangeways Research Laboratory, Worts Causeway, Cambridge CB1 8RN, United Kingdom. Phone: 44-0-1223-740-145; Fax: 44-0-1223-740-163; E-mail: antonis@srl.cam.ac.uk doi: 10.1158/1055-9965.EPI-11-0775 2011 American Association for Cancer Research. Tumor Pathology in BRCA1 and BRCA2 Mutation Carriers www.aacrjournals.org Cancer Epidemiol Biomarkers Prev; 21(1) January 2012 135 on June 25, 2017. © 2012 American Association for Cancer Research. cebp.aacrjournals.org Downloaded from Published OnlineFirst December 5, 2011; DOI: 10.1158/1055-9965.EPI-11-0775